Context Therapeutics Ownership | Who Owns Context Therapeutics?

Context Therapeutics Ownership Summary

Context Therapeutics is owned by 33.11% institutional investors, 2.33% insiders, and 64.57% retail investors. Bioimpact capital is the largest institutional shareholder, holding 15.45% of CNTX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.48% of its assets in Context Therapeutics shares.

CNTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Context Therapeutics	33.11%	2.33%	64.57%
Sector	Healthcare Stocks	279.17%	10.51%	-189.68%
Industry	Biotech Stocks	63.95%	10.67%	25.38%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bioimpact capital	14.71M	15.45%	$9.00M
Avidity partners management lp	7.48M	9.29%	$7.85M
Nextech invest	7.42M	9.22%	$7.79M
Blue owl capital lp	6.36M	7.90%	$6.68M
Deep track capital, lp	7.42M	7.79%	$4.54M
Blackrock	851.70K	5.33%	$1.71M
Franklin resources	4.00M	4.97%	$4.20M
Great point partners	4.68M	4.92%	$2.87M
Vanguard group	3.26M	4.04%	$3.42M
Blackstone	2.44M	3.03%	$2.56M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Bioimpact capital	14.71M	1.55%	$9.00M
Blue owl capital lp	6.36M	1.54%	$6.68M
Great point partners	4.68M	1.52%	$2.87M
Ally bridge group (ny)	1.58M	1.42%	$1.66M
Nextech invest	7.42M	1.26%	$7.79M
Allostery investments lp	950.17K	0.84%	$581.50K
Avidity partners management lp	7.48M	0.77%	$7.85M
Sio capital management	1.33M	0.24%	$812.95K
Deep track capital, lp	7.42M	0.15%	$4.54M
Affinity asset advisors	1.02M	0.14%	$1.07M

Top Buyers

Holder	Shares	% Assets	Change
Franklin resources	4.00M	0.00%	2.15M
Blue owl capital lp	6.36M	1.54%	946.64K
Blackrock	851.70K	-	851.70K
Ubs group	699.13K	0.00%	697.41K
Renaissance	338.44K	0.00%	272.44K

Top Sellers

Holder	Shares	% Assets	Change
Driehaus capital management	-	-	-2.26M
Opaleye management	-	-	-1.11M
Vanguard group	3.26M	0.00%	-489.50K
Altium capital management lp	-	-	-360.00K
Affinity asset advisors	1.02M	0.14%	-305.81K

New Positions

Holder	Shares	% Assets	Change	Value
Blackrock	851.70K	-	851.70K	$1.71M
Landscape capital management	90.00K	0.01%	90.00K	$94.50K
Shay capital	50.00K	0.01%	50.00K	$52.50K
Acadian asset management	16.67K	-	16.67K	$17.00K

Sold Out

Holder	Change
Wells fargo & company/mn	-116.00
Advisornet financial	-200.00
Federation des caisses desjardins du quebec	-400.00
United capital management of ks	-10.00K
Xtx topco	-10.26K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	9	-82.69%	31,512,715	-56.71%	33	0.40%	-	-100.00%	1	-91.67%
Dec 31, 2024	52	23.81%	72,787,034	28.41%	90	1.82%	28	33.33%	12	20.00%
Sep 30, 2024	42	23.53%	56,682,696	-0.62%	70	0.65%	21	-22.22%	10	233.33%
Jun 30, 2024	34	36.00%	57,034,586	1349.37%	103	202.42%	27	170.00%	3	50.00%
Mar 31, 2024	25	4.17%	3,935,132	10.58%	7	17.08%	10	11.11%	2	100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	3.12M	3.48%	-6.75K
Vanguard Total Stock Mkt Idx Inv	2.61M	2.90%	-
Franklin Biotechnology Discv A(acc)USD	2.52M	2.81%	-
Franklin Biotechnology Discovery A	1.48M	1.65%	-
Vanguard Institutional Extnd Mkt Idx Tr	677.81K	0.76%	107.11K
Fidelity Extended Market Index	289.45K	0.32%	4.81K
Calamos Market Neutral Income A	277.81K	0.31%	-
Belfund SICAV Belinvest Equity A USD Acc	260.00K	0.29%	-
BlackRock Extended Equity Market K	104.84K	0.14%	-45.00
Extended Equity Market Fund K	103.74K	0.12%	318.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 21, 2023	Lehr Martin A.	Chief Executive Officer	Buy	$4.90K
Feb 13, 2023	Lehr Martin A.	Chief Executive Officer	Buy	$4.90K
Feb 06, 2023	Lehr Martin A.	Chief Executive Officer	Buy	$4.90K
Jan 30, 2023	Lehr Martin A.	Chief Executive Officer	Buy	$4.90K
Jan 23, 2023	Lehr Martin A.	Chief Executive Officer	Buy	$4.90K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	-
2024 Q3	-	-
2024 Q2	-	-
2024 Q1	-	-
2023 Q2	-	-

CNTX Ownership FAQ

Who Owns Context Therapeutics?

Context Therapeutics shareholders are primarily institutional investors at 33.11%, followed by 2.33% insiders and 64.56% retail investors. The average institutional ownership in Context Therapeutics's industry, Biotech Stocks , is 63.95%, which Context Therapeutics falls below.

Who owns the most shares of Context Therapeutics?

Context Therapeutics’s largest shareholders are Bioimpact capital (14.71M shares, 15.45%), Avidity partners management lp (7.48M shares, 9.29%), and Nextech invest (7.42M shares, 9.22%). Together, they hold 33.96% of Context Therapeutics’s total shares outstanding.

Does Blackrock own Context Therapeutics?

Yes, BlackRock owns 5.33% of Context Therapeutics, totaling 851.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.71M$. In the last quarter, BlackRock increased its holdings by 851.7K shares, a 100.00% change.

Who is Context Therapeutics’s biggest shareholder by percentage of total assets invested?

Bioimpact capital is Context Therapeutics’s biggest shareholder by percentage of total assets invested, with 1.55% of its assets in 14.71M Context Therapeutics shares, valued at 9M$.

Who is the top mutual fund holder of Context Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Context Therapeutics shares, with 3.48% of its total shares outstanding invested in 3.12M Context Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools